|
Dapsone
resources
|
|
|
|
|
|
DRUG INFO
Dapsone
Drug Name:
Dapsone
Indication: For tje treatment and management of Leprosy and Dermatitis Herpetiformis
Pharmacology: Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.
Mechanism Of Action: Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood.
Drug Category: Leprostatic Agents; Antimalarials; Anti-inflammatory Agents; Anti-Infectives; Antimycobacterials; ATC:J04BA02
Brand Names/Synonyms: 1358F; Acedapsone; Araldite Ht; Avlosulfon; Avlosulfone; Avlosulphone; Croysulfone; Croysulphone; DADPS; DDS; DSS; Dapson; Dapsone; Dapsonum; Dds, Diaphenylsulfone; Dds, Pharmaceutical; Diaminodifenilsulfona; Diaminodiphenyl Sulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Dimitone; Diphenasone; Diphone; Disulone; Dubronax; Dumitone; Eporal; F 1358; ICI; K509; Maloprim; Metabolite C; N, N'-Diphenyl Sulfondiamide; NSC 6091D; NSC-6091; Normet; Novophone; P, P'-Sulfonyldianiline; P,P'-Diaminodiphenyl Sulfone; P,P-Diaminodiphenyl Sulphone; P,P-Sulfonylbisbenzamine; P,P-Sulfonylbisbenzenamine; P,P-Sulphonylbisbenzamine; P,P-Sulphonylbisbenzenamine; P,P-Sulphonyldianiline; P-Aminophenyl Sulfone; Recolip; Sulfadione; Sulfanona-Mae; Sulfon-Mere; Sulfona; Sulfona-Mae; Sulfone Ucb; Sulfonyldianiline; Sulphadione; Sulphon-Mere; Sulphonyldianiline; Sumicure S; Tarimyl; Udolac; WR 448
Dosage Forms: TABLET
Absorption: Not Available
Interactions:
DrugBank: Interactions for Dapsone
Interactions for Dapsone:
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double
strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX). During co-administration, systemic levels of TMP
and SMX were essentially unchanged. However, levels of dapsone and its metabolites increased in the presence of
TMP/SMX. Systemic exposure (AUC0-12) of dapsone and N-acetyl-dapsone (NAD) were increased by about 40% and
20% respectively in presence of TMP/SMX. Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine
(DHA) was more than doubled in the presence of TMP/SMX. Exposure from the proposed topical dose is about 1% of that
from the 100 mg oral dose, even when co-administered with TMP/SMX.
Certain concomitant medications (such as rifampin, anticonvulsants, St. Johnís wort) may increase the
formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis. With oral dapsone treatment,
folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic
reactions.
Chemical IUPAC Name: 4-(4-aminophenyl)sulfonylaniline
Chemical Formula: C12H12N2O2S
Half Life: 28 hours (range 10-50 hours)
Drug Type: Approved Drug
# Accession No: APRD00345
CAS Registry Number: 80-08-0
|
|
|
|
|
|
Dapsone News
(When available)
Cabasse to Launch Revolutionary 4-Way Point Source System at CES ... Dec 19, 2005
PR Newswire (press release), Since the Diphone in the 50s (first Cabasse coaxial system) the Cabasse R&D team has always been deeply involved in developing drivers and speakers based on ...
Pivatic takes a tiger leap in international markets Jan 3, 2006
Pressi.com (press release) Mr Seppo Koskinen, M. Sc. (Eng.), has been appointed the Managing Director of Pivatic. He will transfer to Pivatic from Normet Corporation. ...
|
|
|
